Literature DB >> 11292840

Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells.

A N Elayadi1, A Demieville, E V Wancewicz, B P Monia, D R Corey.   

Abstract

2'-O-(2-methoxyethyl) (2'-MOE) RNA possesses favorable pharmocokinetic properties that make it a promising option for the design of oligonucleotide drugs. Telomerase is a ribonucleoprotein that is up-regulated in many types of cancer, but its potential as a target for chemotherapy awaits the development of potent and selective inhibitors. Here we report inhibition of human telomerase by 2'-MOE RNA oligomers that are complementary to the RNA template region. Fully complementary oligomers inhibited telomerase in a cell extract with IC(50) values of 5-10 nM at 37 degrees C. IC(50) values for mismatch-containing oligomers varied with length and phosphorothioate substitution. After introduction into DU 145 prostate cancer cells inhibition of telomerase activity persisted for up to 7 days, equivalent to six population doublings. Inside cells discrimination between complementary and mismatch-containing oligomers increased over time. Our results reveal two oligomers as especially promising candidates for initiation of in vivo preclinical trials and emphasize that conclusions regarding oligonucleotide efficacy and specificity in cell extracts do not necessarily offer accurate predictions of activity inside cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11292840      PMCID: PMC31310          DOI: 10.1093/nar/29.8.1683

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  23 in total

1.  Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells.

Authors:  M A Shammas; C G Simmons; D R Corey; R J Shmookler Reis
Journal:  Oncogene       Date:  1999-11-04       Impact factor: 9.867

Review 2.  An antisense oligonucleotide primer.

Authors:  R I Hogrefe
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1999-08

3.  Chemically modified oligonucleotides exhibit decreased immune stimulation in mice.

Authors:  S Henry; K Stecker; D Brooks; D Monteith; B Conklin; C F Bennett
Journal:  J Pharmacol Exp Ther       Date:  2000-02       Impact factor: 4.030

Review 4.  Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?

Authors:  F Eckstein
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2000-04

Review 5.  Applications of telomerase research in the fight against cancer.

Authors:  K E McKenzie; C B Umbricht; S Sukumar
Journal:  Mol Med Today       Date:  1999-03

6.  Pharmacokinetic properties of several novel oligonucleotide analogs in mice.

Authors:  S T Crooke; M J Graham; J E Zuckerman; D Brooks; B S Conklin; L L Cummins; M J Greig; C J Guinosso; D Kornbrust; M Manoharan; H M Sasmor; T Schleich; K L Tivel; R H Griffey
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

7.  Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death.

Authors:  B Herbert; A E Pitts; S I Baker; S E Hamilton; W E Wright; J W Shay; D R Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

8.  Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats.

Authors:  S M Stepkowski; X Qu; M E Wang; L Tian; W Chen; E V Wancewicz; J F Johnston; C F Bennett; B P Monia
Journal:  Transplantation       Date:  2000-08-27       Impact factor: 4.939

9.  Telomeres shorten during ageing of human fibroblasts.

Authors:  C B Harley; A B Futcher; C W Greider
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

10.  Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression.

Authors:  C M Barton; N R Lemoine
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more
  8 in total

1.  Linear 2' O-Methyl RNA probes for the visualization of RNA in living cells.

Authors:  C Molenaar; S A Marras; J C Slats; J C Truffert; M Lemaître; A K Raap; R W Dirks; H J Tanke
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

Review 2.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

3.  Targeting human telomerase for cancer therapeutics.

Authors:  Lionel Guittat; Patrizia Alberti; Dennis Gomez; Anne De Cian; Gaëlle Pennarun; Thibault Lemarteleur; Chafke Belmokhtar; Rajaa Paterski; Hamid Morjani; Chantal Trentesaux; Eliane Mandine; François Boussin; Patrick Mailliet; Laurent Lacroix; Jean-François Riou; Jean-Louis Mergny
Journal:  Cytotechnology       Date:  2004-06       Impact factor: 2.058

4.  Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.

Authors:  Yingming Li; Bahaa S Malaeb; Zhong-Ze Li; Melissa G Thompson; Zhi Chen; David R Corey; Jer-Tsong Hsieh; Jerry W Shay; Kenneth S Koeneman
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

5.  Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.

Authors:  Delisha A Stewart; Xiaohua Xu; Shelia D Thomas; Donald M Miller; Xiaohou Xu
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

6.  Effects of allicin on both telomerase activity and apoptosis in gastric cancer SGC-7901 cells.

Authors:  Li Sun; Xu Wang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

7.  Inhibition of telomerase by linear-chain fatty acids: a structural analysis.

Authors:  Masako Oda; Takamasa Ueno; Nobuyuki Kasai; Hirotada Takahashi; Hiromi Yoshida; Fumio Sugawara; Kengo Sakaguchi; Hideya Hayashi; Yoshiyuki Mizushina
Journal:  Biochem J       Date:  2002-10-15       Impact factor: 3.857

Review 8.  Structural Features of Nucleoprotein CST/Shelterin Complex Involved in the Telomere Maintenance and Its Association with Disease Mutations.

Authors:  Mohd Amir; Parvez Khan; Aarfa Queen; Ravins Dohare; Mohamed F Alajmi; Afzal Hussain; Asimul Islam; Faizan Ahmad; Imtaiyaz Hassan
Journal:  Cells       Date:  2020-02-04       Impact factor: 7.666

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.